NCT03702374View on ClinicalTrials.gov

Combined Antioxidant Therapy on Oxidative Stress, Mitochondrial Dysfunction Markers in Diabetic Retinopathy

PHASE3CompletedINTERVENTIONAL
Enrollment

132

Participants

Timeline

Start Date

September 26, 2018

Primary Completion Date

November 30, 2020

Study Completion Date

December 31, 2020

Conditions
Diabetic Retinopathy
Interventions
DRUG

Combined antioxidant therapy

It consists in a tablet with lutein (10 mg), astaxanthin (4 mg), Zeaxanthin (1mg), vitamin C (L-ascorbic acid 180mg), vitamin E (DL-alpha tocopherol 30mg), zinc (zinc oxide 20mg), copper (copper sulfate 1mg), taken once a day for 12 months

OTHER

Placebo

It consists in a capsule with 100mg of magnesium oxide.

Trial Locations (1)

44340

Institute of Experimental and Clinical Therapeutics,, Guadalajara

All Listed Sponsors
collaborator

Instituto Mexicano del Seguro Social

OTHER_GOV

lead

University of Guadalajara

OTHER

NCT03702374 - Combined Antioxidant Therapy on Oxidative Stress, Mitochondrial Dysfunction Markers in Diabetic Retinopathy | Biotech Hunter | Biotech Hunter